Aplindore

DB06620InvestigationalSmall molecule

Investigated for use/treatment in parkinson's disease and neurologic disorders.

Mechanism: Pharmacologically active on Dopamine receptor D2
Curator reviewed
Primary indication: Investigated for use/treatment in parkinson's disease and neurologic disorders.Curator reviewed
Formula / weight: C₁₈H₁₈N₂O₃ · 310.353 g/mol (avg)
Also known as: Palindore

Resolves to

Compound

Structure

InChIKeyDYJIKHYBKVODAC-ZDUSSCGKSA-NSMILESO=C1CC2=C3O[C@@H](CNCC4=CC=CC=C4)COC3=CC=C2N1

Targets

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Aplindore, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.